# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
D. Boral Capital analyst Jason Kolbert maintains Co-Diagnostics (NASDAQ:CODX) with a Buy and lowers the price target from $1...
Co-Diagnostics, Inc. (NASDAQ:CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, p...
D. Boral Capital analyst Jason Kolbert maintains Co-Diagnostics (NASDAQ:CODX) with a Buy and maintains $10 price target.
Co-Diagnostics (CODX) shares dropped 24.87% in pre-market trading after an 80.76% surge, despite announcing a strategic partner...